Hazard Ratio 0.62 ( ) P =.024 Larynx and Hypopharynx Overall Survival 166 Patients

Larynx and Hypopharynx OS and PFS

Hazard Ratio 0.67 ( ) P = 0.12 OS “Operable” Hypopharynx and Larynx Patients 123 Patients

LFS in the Operable Patient Population Hazard Ratio 0.59 ( ) P =.03

TAX 324 – Larynx and Hypopharynx Conclusions n Sequential Therapy with TPF Significantly Improves Survival in Advanced Larynx and Hypopharynx Cancer –TPF Reduces Mortality by 38% Compared to PF, p =.02 n Sequential Therapy with TPF Significantly Improves PFS in Advanced Larynx and Hypopharynx Cancer –TPF Improves PFS by 34% Compared to PF, p =.03 –TPF Reduces Surgery by 50%, p =.026 –TPF Reduces Primary Site Surgery

TAX 324 – Larynx and Hypopharynx Rational Speculation n Sequential Therapy With TPF Significantly Improves LFS in Operable Larynx and Hypopharynx Cancer Compared To PF, p =.03 n Since TPF Is Significantly Better Than PF, We Could Reasonably Expect TPF To Be Significantly Better Than Bolus Cisplatin-Based CRT –PF Is Equivalent To Bolus Cisplatin-Based CRT for LFS and Survival* –There Is A Significant Survival and LFS Advantage To TPF Compared to PF *Taylor, 1996, Forastiere, 2006; Lefebvre, 2007